Mechanism of Qili Qiangxin Capsule for Heart Failure Based on miR133a-Endoplasmic Reticulum Stress
中国结合医学杂志(英文版)2024年30卷第5期 页码:398-407
Affiliations:
1.Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Beijing (100700), China
2.Department of Traditional Chinese Medicine, Fuwai Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing (100037), China
Author bio:
Prof. WU Ai-ming, E-mail: wam688@163.com
Funds:
2022 Science and Technology Innovation Project of Dongzhimen Hospital, Beijing University of Chinese Medicine(DZMKJCX-2022-008)
JI Xiao-di, YANG Ding, CUI Xi-yuan, et al. Mechanism of Qili Qiangxin Capsule for Heart Failure Based on miR133a-Endoplasmic Reticulum Stress[J]. Chinese Journal of Integrative Medicine, 2024,30(5):398-407.
JI Xiao-di, YANG Ding, CUI Xi-yuan, et al. Mechanism of Qili Qiangxin Capsule for Heart Failure Based on miR133a-Endoplasmic Reticulum Stress[J]. Chinese Journal of Integrative Medicine, 2024,30(5):398-407. DOI: 10.1007/s11655-024-3654-3.
To investigate the pharmacological mechanism of Qili Qiangxin Capsule (QLQX) improvement of heart failure (HF) based on miR133a-endoplasmic reticulum stress (ERS) pathway.
Methods:
2
A left coronary artery ligation-induced HF after myocardial infarction model was used in this study. Rats were randomly assigned to the sham group
the model group
the QLQX group [0.32 g/(kg•d)]
and the captopril group [2.25 mg/(kg•d)]
15 rats per group
followed by 4 weeks of medication. Cardiac function such as left ventricular ejection fraction (EF)
fractional shortening (FS)
left ventricular systolic pressure (LVSP)
left ventricular end diastolic pressure (LVEDP)
the maximal rate of increase of left ventricular pressure (+dp/dt max)
and the maximal rate of decrease of left ventricular pressure (–dp/dt max) were monitored by echocardiography and hemodynamics. Hematoxylin and eosin (HE) and Masson stainings were used to visualize pathological changes in myocardial tissue. The mRNA expression of miR133a
glucose-regulated protein78 (GRP78)
inositol-requiring enzyme 1 (IRE1)
activating transcription factor 6 (ATF6)
X-box binding protein1 (XBP1)
C/EBP homologous protein (CHOP) and Caspase 12 were detected by RT-PCR. The protein expression of GRP78
p-IRE1/IRE1 ratio
cleaved-ATF6
XBP1-s (the spliced form of XBP1)
CHOP and Caspase 12 were detected by Western blot. TdT-mediated dUTP nick-end labeling (TUNEL) staining was used to detect the rate of apoptosis.
Results:
2
QLQX significantly improved cardiac function as evidenced by increased EF
FS
LVSP
+dp/dt max
-dp/dt max
and decreased LVEDP (
P
<
0.05
P
<
0.01). HE staining showed that QLQX ameliorated cardiac pathologic damage to some extent. Masson staining indicated that QLQX significantly reduced collagen volume fraction in myocardial tissue (
P
<
0.01). Results from RT-PCR and Western blot showed that QLQX significantly increased the expression of miR133a and inhibited the mRNA expressions of GRP78
IRE1
ATF6 and XBP1
as well as decreased the protein expressions of GRP78
cleaved-ATF6 and XBP1-s and decreased p-IRE1/ IRE1 ratio (
P
<
0.05
P
<
0.01). Further studies showed that QLQX significantly reduced the expression of CHOP and Caspase12
resulting in a significant reduction in apoptosis rate (
P
<
0.05
P
<
0.01).
Conclusion:
2
The pharmacological mechanism of QLQX in improving HF is partly attributed to its regulatory effect on the miR133a-IRE1/XBP1 pathway.